Effect of Bariatric Surgery on NAFLD/NASH: a Single-centre Observational Prospective Cohort Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2023 Jul 3

PMID 37400234

Authors

Willy B Theel

Bianca M Boxma-de Klerk

Femme Dirksmeier-Harinck

Elisabeth Fc van Rossum

Danny A Kanhai

Jan A Apers

Bas M van Dalen

Robert J de Knegt

Bojou Neecke

Ellen M van der Zwan

Diederick E Grobbee

Thomas Hankemeier

Janneke Wiebolt

Manuel Castro Cabezas

Affiliations

Soon will be listed here.

Abstract

Introduction: The prevalence of non-alcoholic fatty liver disease (NAFLD) ranges from 25% in the general population to 90% in patients with obesity scheduled for bariatric surgery. NAFLD can progress towards non-alcoholic steatohepatitis (NASH) associated with complications such as cirrhosis, hepatocellular carcinoma and cardiovascular disease. To date, losing weight and lifestyle modifications are the best known treatments for NASH. Bariatric surgery significantly improves NAFLD/NASH in the short term. However, the extent of this improvement is not yet clear and long-term data on the natural course of NAFLD/NASH after bariatric surgery are lacking. The factors involved in NAFLD/NASH regression after bariatric surgery have not been elucidated.

Methods And Analysis: This is an observational prospective cohort study including patients scheduled for bariatric surgery. Extensive metabolic and cardiovascular analyses will be carried out including measurements of carotid intima media thickness and pulse wave velocity. Genomic, proteomic, lipidomic and metabolomic studies will be done. Microbioma analyses before and 1 year after surgery will be done. Transient elastography measurements will be performed before and at 1, 3 and 5 years after surgery. For those with an elevated preoperative transient elastography measurement by Fibroscan, a laparoscopic liver biopsy will be performed during surgery. Primary outcome measures are the change of steatosis and liver fibrosis 5 years after surgery. Secondary outcome measure is the comparison of the transient elastography measurements with the NAFLD Activity Score from the biopsies.

Ethics And Dissemination: The protocol has been approved by the Medical Research Ethics Committees United, Nieuwegein, on 1 March 2022 (registration code R21.103/NL79423.100.21). The study results will be submitted for publication in peer-reviewed journals and data will be presented at scientific meetings.

Trial Registration Number: NCT05499949.

Citing Articles

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease.

Feng G, Valenti L, Wong V, Fouad Y, Yilmaz Y, Kim W Nat Rev Gastroenterol Hepatol. 2023; 21(1):46-56.

PMID: 37798441 DOI: 10.1038/s41575-023-00846-4.

References

Jeong S . Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020; 44(5):640-657. PMC: 7643594. DOI: 10.4093/dmj.2020.0115. View

Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L . Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology. 2006; 44(6):1511-7. DOI: 10.1002/hep.21420. View

Musso G, Cassader M, Rosina F, Gambino R . Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012; 55(4):885-904. DOI: 10.1007/s00125-011-2446-4. View

Oni E, Agatston A, Blaha M, Fialkow J, Cury R, Sposito A . A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis. 2013; 230(2):258-67. DOI: 10.1016/j.atherosclerosis.2013.07.052. View

Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P . Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism. 2017; 71:182-197. DOI: 10.1016/j.metabol.2017.03.013. View

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J . Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015; 149(2):379-88. DOI: 10.1053/j.gastro.2015.04.014. View

Teunis C, Nieuwdorp M, Hanssen N . Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases. Metabolites. 2022; 12(6). PMC: 9227929. DOI: 10.3390/metabo12060514. View

Ratziu V . Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int. 2017; 37 Suppl 1:90-96. DOI: 10.1111/liv.13311. View

10.

Liu S, Wong V, Wong S, Wong G, Lai C, Lam C . A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. Sci Rep. 2021; 11(1):5416. PMC: 7940649. DOI: 10.1038/s41598-021-83782-0. View

11.

Marjot T, Moolla A, Cobbold J, Hodson L, Tomlinson J . Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2019; 41(1). DOI: 10.1210/endrev/bnz009. View

12.

Noureddin M, Vipani A, Bresee C, Todo T, Kim I, Alkhouri N . NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018; 113(11):1649-1659. PMC: 9083888. DOI: 10.1038/s41395-018-0088-6. View

13.

Theel W, Boxma-de Klerk B, Dirksmeier-Harinck F, van Rossum E, Kanhai D, Apers J . Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Obes Rev. 2022; 23(8):e13481. DOI: 10.1111/obr.13481. View

14.

Koehler E, Plompen E, Schouten J, Hansen B, Murad S, Taimr P . Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2015; 63(1):138-47. DOI: 10.1002/hep.27981. View

15.

Courcoulas A, Christian N, ORourke R, Dakin G, Dellinger E, Flum D . Preoperative factors and 3-year weight change in the Longitudinal Assessment of Bariatric Surgery (LABS) consortium. Surg Obes Relat Dis. 2015; 11(5):1109-18. PMC: 4512927. DOI: 10.1016/j.soard.2015.01.011. View

16.

van de Laar A, Nienhuijs S, Apers J, van Rijswijk A, de Zoete J, Gadiot R . The Dutch bariatric weight loss chart: A multicenter tool to assess weight outcome up to 7 years after sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2019; 15(2):200-210. DOI: 10.1016/j.soard.2018.11.024. View

17.

Drolz A, Wolter S, Wehmeyer M, Piecha F, Horvatits T, Schulze Zur Wiesch J . Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond). 2021; 45(10):2197-2204. PMC: 8455320. DOI: 10.1038/s41366-021-00881-8. View

18.

Silva M, Tustumi F, de Miranda Neto A, Dantas A, Santo M, Cecconello I . Gastric Bypass Compared with Sleeve Gastrectomy for Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. Obes Surg. 2021; 31(6):2762-2772. DOI: 10.1007/s11695-021-05412-y. View

19.

Machado M, Marques-Vidal P, Cortez-Pinto H . Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45(4):600-6. DOI: 10.1016/j.jhep.2006.06.013. View

20.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View